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Abstract
Background: Papillary carcinomas that measure 1.0cm or less are diagnosed as papillary thyroid microcarcinomas
(PTMs). The clinical significance and recommendations for management of these PTMs is still evolving. The
objective of the study was to compare the characteristics of small (<5mm) to large (≥ 5mm) papillary thyroid
microcarcinomas.
Methods: Amongst 1459 sequential patients undergoing thyroid surgery at a single center, 132 (9%) cases were
diagnosed with PTM. We performed a retrospective analysis of these cases using Fisher’s Exact Test. The statistical
significance was set at p < 0.05 a priori.
Results: A relationship between large PTM and high risk features was observed only for extra-thyroidal cancer
extension (ETE). Six of 57 large PTM (11%) but none of the 75 small PTM had ETE (p < 0.01). Lymph node metastases
were associated with both small PTM (5/9 cases) and large PTM (4/9 cases). A distant metastases was diagnosed in
association with a small PTM.
Conclusions: For PTM, neither small cancer size, nor the absence of high-risk features, excluded the possibility of
synchronous lymph node metastases.
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Background
Multiple reports have identified a rising incidence of
thyroid cancer over the past several decades, primarily
due to the diagnosis of small papillary carcinomas [1, 2].
According to the World Health Organization, papillary
carcinomas that measure 1.0cm or less are diagnosed as
papillary thyroid microcarcinomas (PTMs) [3]. Recent
work has suggested that PTMs are the most commonly
diagnosed thyroid cancers in individuals who are older
than 45 years, and accounts for almost one quarter of
new diagnoses [1]. The clinical significance and recom-
mendations for management of these PTMs is still
evolving. In general, PTM is considered a clinically very
low risk cancer type that uncommonly causes mortality,
with a greater than 90% disease-free survival after long
term follow up [2, 4, 5]. Reported rates for distant me-
tastases and mortality from PTM are <0.05% [6]. How-
ever, some PTMs exhibit aggressive behaviour, including
the development of a regional and distant metastases,
and even death [7, 8].
The rising incidence of PTM, and its associated mor-
bidity, requires risk stratification and guidelines for
treatment. Currently, treatment of PTM is based upon
stratification of cancer risk for aggressive behaviour,
which is based on patient and cancer characteristics [2,
4]. Cancers considered high risk include those that are:
multifocal, have extrathyroidal extension, have vascular
invasion, are incompletely resected, have lymph node
metastases, especially if multiple nodes are involved,
nodes are > 3cm in largest dimension, or if extra-nodal
cancer extension is present, and if distant metastases are
present. The presence of these high risk features in a
PTM influences the extent of surgery required for treat-
ment [9]. Small PTM size (< 5mm versus ≥ 5mm) has
also been suggested as being important for risk stratifi-
cation, with some reports identifying PTMs ≥ 5mm as
being more likely to have high risk features [8, 10, 11].
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The objective of this study was to determine if small
PTMs (size < 5mm) are clinically and pathologically dif-
ferent from larger PTMs (size 5mm- ≤ 10mm).
Methods
The study protocol was approved by our Research Ethics
Board. This study was a retrospective analysis of data col-
lected prospectively between 2002 and 2012 for 1459 se-
quential patients undergoing thyroid surgery at St. Paul’s
Hospital, a single tertiary care/academic teaching hospital
in Vancouver, Canada. Analysis was limited to cases where
pathology identified a PTM of ≤ 1cm without the presence
of an associated macrocarcinoma (> 1cm). Applying this
inclusion and exclusion criteria resulted in 132 cases for
analysis. This cohort was then examined based on four
clinical and five histopathological characteristics. Clinical
variables evaluated were: age (< 45 versus ≥ 45 years), gen-
der (male versus female), surgery performed (total thy-
roidectomy versus thyroid lobectomy), and surgical
indication (benign disease versus known or suspected can-
cer). Surgical indication was based on pre-operative fine
need aspiration (FNAB) and/or imaging findings. Diagno-
sis of suspicion of malignancy was based upon FNAB
diagnosis of nodules, or pre-operative imaging suspicious
for local or distant metastases. Histopathological variables
evaluated were: cancer multifocality, cancer bilaterality,
extra-thyroidal cancer extension, and the presence of local
and distant cancer metastases, all based on histopatho-
logical reports. Cancers were considered multifocal if ≥ 2
foci were found in one or both thyroid lobes. Size in milli-
meters (< 5mm vs ≥ 5mm) was the independent variable.
The subtype histology of the PTMs were not available for
all cases and was not included in the overall analysis.
Statistical analysis
Statistical differences between groups were determined
using the Chi Square and Fisher’s exact tests as appro-
priate, with a p-value < 0.05 considered statistically dif-
ferent and a priori. Analysis was performed in R.
Results
One hundred thirty-two of 1459 patients (9%) met study
inclusion criteria and made up the study patient
population.
Clinical characteristics
The clinical characteristics and treatment of the study
patient population is summarized in Table 1. Of the 132
patients included, there were 105 (80%) women and 27
(20%) men. The mean age at the time of their procedure
was 50.2 years (range 23–74 years) with 48 patients
(36%) being less than 45 years old and 84 patients (64%)
being aged 45 years or older. The surgical procedure was
a total thyroidectomy for 63 patients (48%) and thyroid
lobectomy for 69 patients (52%). Indication for surgery
was for presumed benign disease in 33 cases (25%) and
for suspicion of or confirmed malignant disease in 99
cases (75%). The suspicion of malignancy was generally
due to an intermediate Fine needle aspiration biopsy of
an associated thyroid nodule > 1cm. Benign pathology
included goiter, Hashimoto’s thyroiditis, thyroid cyst, hy-
perplastic nodules, and Hurthe cell adenomas, all with
PTM that was identified incidentally. All cases with con-
firmed malignancy pre-operatively were papillary thyroid
cancer.
At least 1 histopathologic high risk feature was identi-
fied in 45 patients (34%). Twenty-seven patients (20%)
had 1 high-risk feature, 14 patients (11%) had 2 high risk
features and 4 (3%) had 3 high risk features. No patients
had 4 or 5 high risk histopathologic features. Multifocal-
ity was identified in 29 patients (28%), bilaterality in 8
patients (6% of total, 27% with multifocal disease), extra-
thyroidal cancer extension in 6 patients (5%), lymph
node metastases present at diagnosis in 9 patients (7%)
and distant metastases present at diagnosis in 1 patient
(0.7%). The study population’s characteristics are sum-
marized in Table 2.
Chi square or Fisher’s Exact test comparison for pa-
tient and surgical variables of interest failed to identify a
difference between small or large PTM (Table 1). Exam-
ination of high risk features revealed that extrathyroidal
cancer extension was present significantly more often in
large PTM (p = 0.005). Other high risk features were not
differentially identified based on cancer size (Table 2).













<45 22 26 48 (36%) p = 0.08
≥45 53 31 84 (64%)
Gender
Male 11 16 27 (20%) p = 0.09
Female 64 41 105
(80%)
Surgery
Total Thyroidectomy 37 26 63 (48%) p = 0.80
Thyroid Lobectomy 38 31 69 (52%)
Surgical Indication
Benign 20 13 33 (25%) p = 0.76
Malignant 55 44 99 (75%)
Benign pathology included goiter, Hashimoto’s thyroiditis, thyroid cyst,
hyperplastic nodules, and Hurthe cell adenomas associated with papillary
thyroid microcarcinoma. Malignant pathology (confirmed or suspected) was
based on fine needle aspiration biopsy of nodules or pre-operative imaging.
All cases with confirmed malignancy pre-operatively were papillary
thyroid cancer
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The 9 patients who had lymph node metastases present
at the time of their cancer diagnosis were further stud-
ied. Six of nine patients (67%) had bilateral disease and
two of the six also had extrathyroidal extension (both
large PTM), while two others had associated bilateral
disease (both small PTM), including one patient with
distant metastases from a 3mm cancer. Three of the
nine patients (33%) had lymph node metastases in the
absence of any high risk features (Table 3).
Discussion
PTM diagnosis is very common with almost half of all
new papillary thyroid cancer (PTC) diagnoses being a
PTM. Following thyroid surgery, pathologic identification
of PTM ranges from 1–24% of surgical specimens [2, 5,
10], and 6–36% of autopsy specimens [2, 5]. Analysis of
the Surveillance, Epidemiology and End Results database
revealed that PTM in patients older than 45 years is now
the most commonly diagnosed PTC [1]. Our observed
rate of PTM diagnosed from surgical specimens in the ab-
sence of a thyroid macrocarcinoma was 9%, and was con-
sistent with Canadian autopsy (6%) [12], international
autopsy (3–18%) [2] and pathology data (1–24%) depend-
ing on the extent of surgical resection [2, 11].
Guidelines regarding the surgical management of PTC
have continued to evolve and are currently based on
clinical and pathological characteristics of the diagnosed
individual and their thyroid cancer, respectively [9}.
However, debate still exists regarding whether PTM
should be managed in a manner similar to larger PTC
[4]. PTM usually has an excellent prognosis and current
American Thyroid Association Guidelines recommend
that thyroid lobectomy alone is adequate treatment for
unifocal intrathyroiodal cancers in the absence of a prior
history of head and neck irradiation, familial thyroid car-
cinoma, or clinically detectable cervical metastases. As
there are no features of PTM that can reliably identify
the small subset of patients who will go on to develop
clinically significant cancer progression, an active sur-
veillance approach that involves close clinical and ultra-
sound PTM follow up, has currently not been adopted
by the vast majority of centers [9]. An observational
study, with non-surgical management of PTM, reported
3mm of growth in 6% of patients, with 1.4% of patients
developing lateral lymph node metastases at 5 years of
follow-up. These authors have suggested non-operative
management of PTM in the absence of high risk features
[13]. However, other groups have encouraged a surgical
approach, which has shifted from thyroid lobectomy to
total thyroidectomy, and some groups even recommend
nodal dissection of the central neck. Proponents of the
latter approach recognize the relationship between high
risk features and disease recurrence [14, 15].
High risk features are often present in PTM and one-
third of our patients had at least 1 high risk feature iden-
tified after pathological examination. While distant me-
tastases were uncommon in our series (< 1%), consistent
with other reports [6], multifocality was observed in al-
most a third of cases (28%) and 27% of these cases had
bilateral disease. Reported multifocality rates for PTM
have ranged from 15–43% [2, 15], with contralateral ma-
lignancy identified in up to 53% of cases [16]. Interest-
ingly, multifocality is believed to reflect multiple
independent tumors of different clonal origin, as op-
posed to intraglandular cancer metastases [17]. While
the incidence of PTC multifocality is not related to
tumor size [18] as we observed in the current study, it
has been reported to be an independent risk factor for
cancer recurrence [6, 17]. However, the prognostic sig-
nificance of contralateral PTM is controversial. Given
that only 5–10% of the PTCs recur, some investigators
have suggested that recurrence can be treated when de-
tected clinically, while other investigators have argued
that reoperative surgery carries additional risks that need
to be weighted appropriately [14]. The presence of
lymph node metastases at the time of diagnosis also
Table 2 High Risk Characteristics of Papillary Thyroid
Microcarcinoma Patient Population








Cancer Bilaterality 6 (8) 2 (4) 8 (6) 0.48
Cancer Multifocality 21(28) 17 (30) 38 (29) 0.97
Extrathyroidal Cancer
Extension
0 (0) 6 (11) 6 (5) p = 0.005
Lymph Node
Metastases
5 (7) 4 (7) 9 (7) 0.78
Distant Metastases 1 (1) 0 (0) 1 (0.7) 0.89
Total 24 29 53
Table 3 Patient Population With Lymph Node Metastases
Pt Age Size mm Histology Bilateral Multifocal ETE LN Mets Dis
Mets
7 < 45 9 PTMC – – – + –
1 < 45 8 PTMCvF – + + + –
8 ≥ 45 6 PTMC – – – + –
3 ≥ 45 5 PTMC – + + + –
2 ≥ 45 3 PTMCvS + + – + –
5 < 45 3 PTMC – + – + –
6 ≥ 45 3 PTMCvF + + – + +
4 ≥ 45 2.5 PTMCvS – + – + –
9 ≥ 45 2 PMTCvF – – – + –
Pt patient, Bilateral bilaterality, Multifocal multifocality, ETE extra-thyroidal ex-
tension, LN Mets lymph node metastasis, Dis Mets distant metastasis, PTMC
papillary thyroid microcarcinoma, vF variant follicular, vS variant sclerosing
+, present; -, absent
Bold values, LN metastasis in absence of any other high risk features
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influences cancer recurrence risk and has been reported
in 5–51% of cases [2, 15]. The current study observed a
7% rate of nodal disease at the time of PTC diagnosis is
at the lower end of this range, but is consistent with the
9% nodal disease risk that has been recently associated
with PTM [15]. This low rate of lymph node metastases
may be an underestimate as the practice of central neck
dissection for these cases is variable. Long-term follow-
up of PTM has found that the presence of multifocality
and lymph node metastases at diagnoses increases the
risk of developing subsequent nodal disease, 11% of
multifocal PTM recurred compared with 4% of unifocal
PTM tumors [19].
Three of nine patients diagnosed with lymph node me-
tastases at the time of their diagnosis had no other high
risk features present. The presence of nodal metastasis in
association with PTM is believed to represent different
underlying cancer biology when compared with PTM not
associated with nodal metastases [5]. Aggressive biological
behavior may be related to molecular characteristics not
yet well understood. Recent reports have identified mo-
lecular BRAF mutations, present in 17–52% of PTM, as
potential early genetic lesions in PTC [2, 20]. Presence of
BRAF mutations are associated with high risk features, in-
cluding extrathyroidal cancer extension (ETE) and multi-
focality, and are also predictive of an increased risk of
lateral compartment nodal disease [20]. Lin and colleagues
have suggested that pre-operative screening for BRAF mu-
tation using fine needle aspirate biopsy could potentially
guide the initial treatment of PTM, with positive BRAF
status requiring more aggressive therapy [20]. Other re-
cent studies have found that combining BRAF mutations
with a panel of other molecular prognosticators may im-
prove its clinical utility [9].
Some investigators have reported that the tumor size
of PTM (< 5 vs ≥ 5mm) may be related to aggressive
cancer behavior, with larger PTMs being more likely to
have high risk features and nodal metastasis [10, 21].
Other groups have found no relationship between PTM
size and the presence of high risk features [22, 23]. Our
study found that the size of PTM had little relationship
with the presence of high risk features. Only ETE was
significantly more commonly present in larger than
smaller PTM. While the overall rate of ETE was low
(5%), these observations were consistent with prior re-
ports (2–21%) [2, 5]. Kim et al. [24] found that the pres-
ence of ETE was directly related to the PTM size but
not with the risk of cancer recurrence. Other groups
have evaluated the relationship between cancer size and
high risk features concluded that PTM size did not influ-
ence patient outcomes [10, 21].
The current study has several limitations. It is a retro-
spective analysis from a single institution and results
may not be generalizable to all populations. However,
the prospective data collection from a multi-cultural
catchment area in a publically funded health care system
provides support of the representative nature of the
sample. The incidental identification of PTC after sur-
gery for benign disease implies that lymph nodes could
be under-sampled, and presence of metastatic disease
may be higher than our results suggest. As well, out-
come and follow-up data is not available and thus no
prognostic information can be inferred from this
analysis.
Conclusions
The diagnosis of PTM after thyroid surgery presents the
thyroid cancer management team with a dilemma. Neither
PTM size, nor the absence of high risk features, excluded
the possibility of synchronous lymph node metastases.
While some argue that high risk features should prompt
surgical management consistent with PTC >1cm, further
study that includes the evaluation of the role of thyroid
cancer molecular prognostications is required in order to
identify the optimal management algorithm for this com-
mon endocrine malignancy.
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